Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 79

1.

Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study.

Lowery MA, Burris HA 3rd, Janku F, Shroff RT, Cleary JM, Azad NS, Goyal L, Maher EA, Gore L, Hollebecque A, Beeram M, Trent JC, Jiang L, Fan B, Aguado-Fraile E, Choe S, Wu B, Gliser C, Agresta SV, Pandya SS, Zhu AX, Abou-Alfa GK.

Lancet Gastroenterol Hepatol. 2019 Sep;4(9):711-720. doi: 10.1016/S2468-1253(19)30189-X. Epub 2019 Jul 9.

PMID:
31300360
2.

First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers.

Sikic BI, Lakhani N, Patnaik A, Shah SA, Chandana SR, Rasco D, Colevas AD, O'Rourke T, Narayanan S, Papadopoulos K, Fisher GA, Villalobos V, Prohaska SS, Howard M, Beeram M, Chao MP, Agoram B, Chen JY, Huang J, Axt M, Liu J, Volkmer JP, Majeti R, Weissman IL, Takimoto CH, Supan D, Wakelee HA, Aoki R, Pegram MD, Padda SK.

J Clin Oncol. 2019 Apr 20;37(12):946-953. doi: 10.1200/JCO.18.02018. Epub 2019 Feb 27.

PMID:
30811285
3.

Proteomics and Metabolomics in Pregnancy-An Overview.

Vora N, Kalagiri R, Mallett LH, Oh JH, Wajid U, Munir S, Colon N, Raju VN, Beeram MR, Uddin MN.

Obstet Gynecol Surv. 2019 Feb;74(2):111-125. doi: 10.1097/OGX.0000000000000646. Review.

PMID:
30756125
4.

The Tri-phasic Role of Hydrogen Peroxide in Blood-Brain Barrier Endothelial cells.

Anasooya Shaji C, Robinson BD, Yeager A, Beeram MR, Davis ML, Isbell CL, Huang JH, Tharakan B.

Sci Rep. 2019 Jan 15;9(1):133. doi: 10.1038/s41598-018-36769-3.

5.

Correction to: A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer.

Patnaik A, Gordon M, Tsai F, Papadopoulos KP, Rasco D, Beeram M, Fu S, Janku F, Hynes SM, Gundala SR, Willard MD, Zhang W, Lin AB, Hong D.

Cancer Chemother Pharmacol. 2018 Sep;82(3):419. doi: 10.1007/s00280-018-3641-5.

PMID:
30014222
6.

A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer.

Patnaik A, Gordon M, Tsai F, Papadopoulos KP, Rasco D, Beeram M, Fu S, Janku F, Hynes SM, Gundala SR, Willard MD, Zhang W, Lin AB, Hong D.

Cancer Chemother Pharmacol. 2018 Sep;82(3):407-418. doi: 10.1007/s00280-018-3623-7. Epub 2018 Jun 20. Erratum in: Cancer Chemother Pharmacol. 2018 Jul 16;:. Papadopoulous, Kyri [corrected to Papadopoulos, Kyriakos P] and Beeram, S Muralidhar [corrected to Beeram, Muralidhar].

7.

Phase 1 and pharmacokinetic study of LY3007113, a p38 MAPK inhibitor, in patients with advanced cancer.

Goldman JW, Rosen LS, Tolcher AW, Papadopoulos K, Beeram M, Shi P, Pitou C, Bell R, Kulanthaivel P, Zhang X, Fink A, Chan EM, Shahir A, Farrington D, Patnaik A.

Invest New Drugs. 2018 Aug;36(4):629-637. doi: 10.1007/s10637-017-0532-2. Epub 2017 Dec 1.

8.

Diabetes and pre-eclampsia affecting pregnancy: a retrospective cross-sectional study.

Kalagiri RR, Vora N, Wilson JL, Afroze SH, Raju VN, Govande V, Beeram MR, Kuehl TJ, Uddin MN.

J Investig Med. 2018 Apr;66(4):728-732. doi: 10.1136/jim-2017-000537. Epub 2017 Nov 22.

PMID:
29170244
9.

Congenital midline nasal anomalies.

Vora N, Kalagiri R, Guillory B, Shetty A, Raju VN, Powitzky RK, Beeram MR.

Proc (Bayl Univ Med Cent). 2017 Oct;30(4):459-460.

10.

Two Phase 1 dose-escalation studies exploring multiple regimens of litronesib (LY2523355), an Eg5 inhibitor, in patients with advanced cancer.

Infante JR, Patnaik A, Verschraegen CF, Olszanski AJ, Shaheen M, Burris HA, Tolcher AW, Papadopoulos KP, Beeram M, Hynes SM, Leohr J, Lin AB, Li LQ, McGlothlin A, Farrington DL, Westin EH, Cohen RB.

Cancer Chemother Pharmacol. 2017 Feb;79(2):315-326. doi: 10.1007/s00280-016-3205-5. Epub 2017 Jan 17.

PMID:
28097385
11.

Multicenter neonatal databases: Trends in research uses.

Creel LM, Gregory S, McNeal CJ, Beeram MR, Krauss DR.

BMC Res Notes. 2017 Jan 13;10(1):42. doi: 10.1186/s13104-016-2336-4. Review.

12.

Attenuation of Blood-Brain Barrier Breakdown and Hyperpermeability by Calpain Inhibition.

Alluri H, Grimsley M, Anasooya Shaji C, Varghese KP, Zhang SL, Peddaboina C, Robinson B, Beeram MR, Huang JH, Tharakan B.

J Biol Chem. 2016 Dec 30;291(53):26958-26969. doi: 10.1074/jbc.M116.735365. Epub 2016 Nov 8.

13.

Bilateral congenital pseudoarthrosis of the clavicles in a newborn.

Kalagiri RR, Govande V, Hemingway M, Beeram MR.

Proc (Bayl Univ Med Cent). 2016 Oct;29(4):387-388.

14.

First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas.

Patnaik A, Appleman LJ, Tolcher AW, Papadopoulos KP, Beeram M, Rasco DW, Weiss GJ, Sachdev JC, Chadha M, Fulk M, Ejadi S, Mountz JM, Lotze MT, Toledo FG, Chu E, Jeffers M, Peña C, Xia C, Reif S, Genvresse I, Ramanathan RK.

Ann Oncol. 2016 Oct;27(10):1928-40. doi: 10.1093/annonc/mdw282.

15.

Maternal pre-eclampsia as a risk factor for necrotizing enterocolitis.

Perger L, Mukhopadhyay D, Komidar L, Wiggins-Dohlvik K, Uddin MN, Beeram M.

J Matern Fetal Neonatal Med. 2016;29(13):2098-103. doi: 10.3109/14767058.2015.1076386. Epub 2015 Aug 28.

PMID:
27480208
16.

Phase 1 study to evaluate the effect of the MEK inhibitor trametinib on cardiac repolarization in patients with solid tumours.

Patnaik A, Tolcher A, Papadopoulos KP, Beeram M, Rasco D, Werner TL, Bauman JW, Scheuber A, Cox DS, Patel BR, Zhou Y, Hamid M, Schramek D, Sharma S.

Cancer Chemother Pharmacol. 2016 Sep;78(3):491-500. doi: 10.1007/s00280-016-3090-y. Epub 2016 Jul 8.

PMID:
27392790
17.

Apoptotic and stress signaling markers are augmented in preeclamptic placenta and umbilical cord.

Afroze SH, Kalagiri RR, Reyes M, Zimmerman JD, Beeram MR, Drever N, Zawieja DC, Kuehl TJ, Uddin MN.

BBA Clin. 2016 May 25;6:25-30. doi: 10.1016/j.bbacli.2016.05.003. eCollection 2016 Dec.

18.

Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors.

Patnaik A, Rosen LS, Tolaney SM, Tolcher AW, Goldman JW, Gandhi L, Papadopoulos KP, Beeram M, Rasco DW, Hilton JF, Nasir A, Beckmann RP, Schade AE, Fulford AD, Nguyen TS, Martinez R, Kulanthaivel P, Li LQ, Frenzel M, Cronier DM, Chan EM, Flaherty KT, Wen PY, Shapiro GI.

Cancer Discov. 2016 Jul;6(7):740-53. doi: 10.1158/2159-8290.CD-16-0095. Epub 2016 May 23.

19.

Inflammation in Complicated Pregnancy and Its Outcome.

Kalagiri RR, Carder T, Choudhury S, Vora N, Ballard AR, Govande V, Drever N, Beeram MR, Uddin MN.

Am J Perinatol. 2016 Dec;33(14):1337-1356. doi: 10.1055/s-0036-1582397. Epub 2016 May 9. Review.

PMID:
27159203
20.

Melatonin Preserves Blood-Brain Barrier Integrity and Permeability via Matrix Metalloproteinase-9 Inhibition.

Alluri H, Wilson RL, Anasooya Shaji C, Wiggins-Dohlvik K, Patel S, Liu Y, Peng X, Beeram MR, Davis ML, Huang JH, Tharakan B.

PLoS One. 2016 May 6;11(5):e0154427. doi: 10.1371/journal.pone.0154427. eCollection 2016.

21.

Safety and efficacy of packed red blood cell transfusions at different doses in very low birth weight infants.

Mallett LH, Govande VP, Shetty A, Beeram MR.

Proc (Bayl Univ Med Cent). 2016 Apr;29(2):128-30.

22.

Neonatal Thrombocytopenia as a Consequence of Maternal Preeclampsia.

Kalagiri RR, Choudhury S, Carder T, Govande V, Beeram MR, Uddin MN.

AJP Rep. 2016 Mar;6(1):e42-7. doi: 10.1055/s-0035-1565923. Epub 2015 Oct 28.

23.

A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer.

Patnaik A, Haluska P, Tolcher AW, Erlichman C, Papadopoulos KP, Lensing JL, Beeram M, Molina JR, Rasco DW, Arcos RR, Kelly CS, Wijayawardana SR, Zhang X, Stancato LF, Bell R, Shi P, Kulanthaivel P, Pitou C, Mulle LB, Farrington DL, Chan EM, Goetz MP.

Clin Cancer Res. 2016 Mar 1;22(5):1095-102. doi: 10.1158/1078-0432.CCR-15-1718. Epub 2015 Nov 18. Erratum in: Clin Cancer Res. 2016 May 15;22(10 ):2596.

24.

A Phase I First-in-Human Study of Nesvacumab (REGN910), a Fully Human Anti-Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients with Advanced Solid Tumors.

Papadopoulos KP, Kelley RK, Tolcher AW, Razak AR, Van Loon K, Patnaik A, Bedard PL, Alfaro AA, Beeram M, Adriaens L, Brownstein CM, Lowy I, Kostic A, Trail PA, Gao B, DiCioccio AT, Siu LL.

Clin Cancer Res. 2016 Mar 15;22(6):1348-55. doi: 10.1158/1078-0432.CCR-15-1221. Epub 2015 Oct 21.

25.

Clinical pharmacology characterization of RG7112, an MDM2 antagonist, in patients with advanced solid tumors.

Patnaik A, Tolcher A, Beeram M, Nemunaitis J, Weiss GJ, Bhalla K, Agrawal M, Nichols G, Middleton S, Beryozkina A, Sarapa N, Peck R, Zhi J.

Cancer Chemother Pharmacol. 2015 Sep;76(3):587-95. doi: 10.1007/s00280-015-2830-8. Epub 2015 Jul 26.

PMID:
26210682
26.

In the Cradle of Death: A Rare Case of Intrauterine Herpes Simplex Virus Infection.

Co MA, Koneru M, Santiago J, Beeram MR, Uddin MN.

Clin Pediatr (Phila). 2016 Mar;55(3):301-3. doi: 10.1177/0009922815596071. Epub 2015 Jul 15. No abstract available.

PMID:
26183325
27.

Trends in the neonatal mortality rate in the last decade with respect to demographic factors and health care resources.

Govande V, Ballard AR, Koneru M, Beeram M.

Proc (Bayl Univ Med Cent). 2015 Jul;28(3):304-6.

28.

Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors.

Patnaik A, Kang SP, Rasco D, Papadopoulos KP, Elassaiss-Schaap J, Beeram M, Drengler R, Chen C, Smith L, Espino G, Gergich K, Delgado L, Daud A, Lindia JA, Li XN, Pierce RH, Yearley JH, Wu D, Laterza O, Lehnert M, Iannone R, Tolcher AW.

Clin Cancer Res. 2015 Oct 1;21(19):4286-93. doi: 10.1158/1078-0432.CCR-14-2607. Epub 2015 May 14.

29.

Hyperglycemia down-regulates cGMP-dependent protein kinase I expression in first trimester cytotrophoblast cells.

Nguyen T, Lin S, Pantho AF, Kohl-Thomas BM, Beeram MR, Zawieja DC, Kuehl TJ, Uddin MN.

Mol Cell Biochem. 2015 Jul;405(1-2):81-8. doi: 10.1007/s11010-015-2398-y. Epub 2015 Apr 12.

PMID:
25863494
30.

Elevation of (Pro)Renin and (Pro)Renin Receptor in Preeclampsia.

Thomason J, Reyes M, Allen SR, Jones RO, Beeram MR, Kuehl TJ, Suzuki F, Uddin MN.

Am J Hypertens. 2015 Oct;28(10):1277-84. doi: 10.1093/ajh/hpv019. Epub 2015 Mar 11.

PMID:
25767135
31.

Pre-eclampsia has an adverse impact on maternal and fetal health.

Lin S, Leonard D, Co MA, Mukhopadhyay D, Giri B, Perger L, Beeram MR, Kuehl TJ, Uddin MN.

Transl Res. 2015 Apr;165(4):449-63. doi: 10.1016/j.trsl.2014.10.006. Epub 2014 Oct 16. Review.

PMID:
25468481
32.

Suppression of aldosterone and progesterone in preeclampsia.

Uddin MN, Horvat D, Jones RO, Beeram MR, Zawieja DC, Perger L, Sprague DCC, Kuehl TJ.

J Matern Fetal Neonatal Med. 2015 Jul;28(11):1296-1301. doi: 10.3109/14767058.2014.951627. Epub 2014 Aug 28.

PMID:
25164552
33.

NSAID use reduces breast cancer recurrence in overweight and obese women: role of prostaglandin-aromatase interactions.

Bowers LW, Maximo IX, Brenner AJ, Beeram M, Hursting SD, Price RS, Tekmal RR, Jolly CA, deGraffenried LA.

Cancer Res. 2014 Aug 15;74(16):4446-57. doi: 10.1158/0008-5472.CAN-13-3603.

34.

Phase I first-in-human study of CUDC-101, a multitargeted inhibitor of HDACs, EGFR, and HER2 in patients with advanced solid tumors.

Shimizu T, LoRusso PM, Papadopoulos KP, Patnaik A, Beeram M, Smith LS, Rasco DW, Mays TA, Chambers G, Ma A, Wang J, Laliberte R, Voi M, Tolcher AW.

Clin Cancer Res. 2014 Oct 1;20(19):5032-40. doi: 10.1158/1078-0432.CCR-14-0570. Epub 2014 Aug 8.

35.

A synthetic thiourea-based tripodal receptor that impairs the function of human first trimester cytotrophoblast cells.

Horvat D, Khansari ME, Pramanik A, Beeram MR, Kuehl TJ, Hossain MA, Uddin MN.

Int J Environ Res Public Health. 2014 Jul 21;11(7):7456-69. doi: 10.3390/ijerph110707456.

36.

Intrauterine growth restriction and prematurity influence regulatory T cell development in newborns.

Mukhopadhyay D, Weaver L, Tobin R, Henderson S, Beeram M, Newell-Rogers MK, Perger L.

J Pediatr Surg. 2014 May;49(5):727-32. doi: 10.1016/j.jpedsurg.2014.02.055. Epub 2014 Feb 22.

PMID:
24851757
37.

Phase II study evaluating the efficacy, safety, and pharmacodynamic correlative study of dual antiangiogenic inhibition using bevacizumab in combination with sorafenib in patients with advanced malignant melanoma.

Mahalingam D, Malik L, Beeram M, Rodon J, Sankhala K, Mita A, Benjamin D, Ketchum N, Michalek J, Tolcher A, Wright J, Sarantopoulos J.

Cancer Chemother Pharmacol. 2014 Jul;74(1):77-84. doi: 10.1007/s00280-014-2479-8. Epub 2014 May 10.

PMID:
24817603
38.

A Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumors.

Patnaik A, LoRusso PM, Messersmith WA, Papadopoulos KP, Gore L, Beeram M, Ramakrishnan V, Kim AH, Beyer JC, Mason Shih L, Darbonne WC, Xin Y, Yu R, Xiang H, Brachmann RK, Weekes CD.

Cancer Chemother Pharmacol. 2014 May;73(5):951-60. doi: 10.1007/s00280-014-2426-8. Epub 2014 Mar 17.

PMID:
24633809
39.

A phase I study of the human monoclonal anti-NRP1 antibody MNRP1685A in patients with advanced solid tumors.

Weekes CD, Beeram M, Tolcher AW, Papadopoulos KP, Gore L, Hegde P, Xin Y, Yu R, Shih LM, Xiang H, Brachmann RK, Patnaik A.

Invest New Drugs. 2014 Aug;32(4):653-60. doi: 10.1007/s10637-014-0071-z. Epub 2014 Mar 7.

PMID:
24604265
40.

Reactive oxygen species-caspase-3 relationship in mediating blood-brain barrier endothelial cell hyperpermeability following oxygen-glucose deprivation and reoxygenation.

Alluri H, Stagg HW, Wilson RL, Clayton RP, Sawant DA, Koneru M, Beeram MR, Davis ML, Tharakan B.

Microcirculation. 2014 Feb;21(2):187-95. doi: 10.1111/micc.12110.

PMID:
24372803
41.

Phase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer.

Patnaik A, Papadopoulos KP, Tolcher AW, Beeram M, Urien S, Schaaf LJ, Tahiri S, Bekaii-Saab T, Lokiec FM, Rezaï K, Buchbinder A.

Cancer Chemother Pharmacol. 2013 Jun;71(6):1499-506. doi: 10.1007/s00280-013-2149-2. Epub 2013 Mar 30.

42.

A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancer.

Beeram M, Krop IE, Burris HA, Girish SR, Yu W, Lu MW, Holden SN, Modi S.

Cancer. 2012 Dec 1;118(23):5733-40. doi: 10.1002/cncr.27622. Epub 2012 May 30.

43.

The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer.

Shimizu T, Tolcher AW, Papadopoulos KP, Beeram M, Rasco DW, Smith LS, Gunn S, Smetzer L, Mays TA, Kaiser B, Wick MJ, Alvarez C, Cavazos A, Mangold GL, Patnaik A.

Clin Cancer Res. 2012 Apr 15;18(8):2316-25. doi: 10.1158/1078-0432.CCR-11-2381. Epub 2012 Jan 19.

44.

Utilization of umbilical cord blood for the evaluation of group B streptococcal sepsis screening.

Beeram MR, Loughran C, Cipriani C, Govande V.

Clin Pediatr (Phila). 2012 May;51(5):447-53. doi: 10.1177/0009922811431882. Epub 2011 Dec 22.

PMID:
22199177
45.

Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer.

Gupta M, Lorusso PM, Wang B, Yi JH, Burris HA 3rd, Beeram M, Modi S, Chu YW, Agresta S, Klencke B, Joshi A, Girish S.

J Clin Pharmacol. 2012 May;52(5):691-703. doi: 10.1177/0091270011403742. Epub 2011 Sep 27.

PMID:
21953571
46.

Tesetaxel, a new oral taxane, in combination with capecitabine: a phase I, dose-escalation study in patients with advanced solid tumors.

Saif MW, Sarantopoulos J, Patnaik A, Tolcher AW, Takimoto C, Beeram M.

Cancer Chemother Pharmacol. 2011 Dec;68(6):1565-73. doi: 10.1007/s00280-011-1639-3. Epub 2011 May 6.

PMID:
21547572
47.

Mechanism-based pharmacokinetic/pharmacodynamic model for troxacitabine-induced neutropenia in cancer patients.

Ng CM, Patnaik A, Beeram M, Lin CC, Takimoto CH.

Cancer Chemother Pharmacol. 2011 May;67(5):985-94. doi: 10.1007/s00280-010-1393-y. Epub 2010 Jul 8.

PMID:
20614121
48.

Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer.

Krop IE, Beeram M, Modi S, Jones SF, Holden SN, Yu W, Girish S, Tibbitts J, Yi JH, Sliwkowski MX, Jacobson F, Lutzker SG, Burris HA.

J Clin Oncol. 2010 Jun 1;28(16):2698-704. doi: 10.1200/JCO.2009.26.2071. Epub 2010 Apr 26.

PMID:
20421541
49.

Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies.

Lin CC, Beeram M, Rowinsky EK, Takimoto CH, Ng CM, Geyer CE Jr, Denis LJ, De Bono JS, Hao D, Tolcher AW, Rha SY, Jolivet J, Patnaik A.

Cancer Chemother Pharmacol. 2009 Dec;65(1):167-75. doi: 10.1007/s00280-009-1020-y. Epub 2009 May 16.

PMID:
19449006
50.

Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors.

Mita AC, Denis LJ, Rowinsky EK, Debono JS, Goetz AD, Ochoa L, Forouzesh B, Beeram M, Patnaik A, Molpus K, Semiond D, Besenval M, Tolcher AW.

Clin Cancer Res. 2009 Jan 15;15(2):723-30. doi: 10.1158/1078-0432.CCR-08-0596.

Supplemental Content

Loading ...
Support Center